Investigational Drug Information for HDM201
✉ Email this page to a colleague
What is the drug development status for HDM201?
HDM201 is an investigational drug.
There have been 16 clinical trials for HDM201.
The most recent clinical trial was a Phase 1 trial, which was initiated on January 28th 2020.
The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, Myeloid, and Leukemia. The leading clinical trial sponsors are Novartis Pharmaceuticals, Centre Leon Berard, and Novartis.
There are eighteen US patents protecting this investigational drug and three hundred and forty-six international patents.
Summary for HDM201
| US Patents | 18 |
| International Patents | 346 |
| US Patent Applications | 190 |
| WIPO Patent Applications | 79 |
| Japanese Patent Applications | 29 |
| Clinical Trial Progress | Phase 1 (2020-01-28) |
| Vendors | 38 |
Recent Clinical Trials for HDM201
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant | Novartis Pharmaceuticals | Phase 1/Phase 2 |
| Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment | Novartis Pharmaceuticals | Phase 1 |
| A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy. | Novartis Pharmaceuticals | Phase 1/Phase 2 |
Clinical Trial Summary for HDM201
Top disease conditions for HDM201
Top clinical trial sponsors for HDM201
US Patents for HDM201
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| HDM201 | ⤷ Try a Trial | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | NOVARTIS AG (Basel, CH) | ⤷ Try a Trial |
| HDM201 | ⤷ Try a Trial | Pharmaceutical combinations | Novartis AG (Basel, CH) | ⤷ Try a Trial |
| HDM201 | ⤷ Try a Trial | Anti-CDH6 antibody drug conjugates | Novartis AG (Basel, CH) | ⤷ Try a Trial |
| HDM201 | ⤷ Try a Trial | Modified cyclic dinucleotide compounds | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) | ⤷ Try a Trial |
| HDM201 | ⤷ Try a Trial | Compositions and methods for activating "stimulator of interferon gene"--dependent signalling | ADURO BIOTECH, INC. (Berkeley, CA) | ⤷ Try a Trial |
| HDM201 | ⤷ Try a Trial | Antibody molecules to TIM-3 and uses thereof | Novartis AG (Basel, CH) DANA-FARBER CANCER INSTITUTE, INC. (Boston, MA) Children's Medical Center Corporation (Boston, MA) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for HDM201
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| HDM201 | Australia | AU2016238436 | 2035-03-25 | ⤷ Try a Trial |
| HDM201 | Brazil | BR112017016817 | 2035-03-25 | ⤷ Try a Trial |
| HDM201 | Canada | CA2976766 | 2035-03-25 | ⤷ Try a Trial |
| HDM201 | China | CN107667092 | 2035-03-25 | ⤷ Try a Trial |
| HDM201 | European Patent Office | EP3274344 | 2035-03-25 | ⤷ Try a Trial |
| HDM201 | Japan | JP2018509442 | 2035-03-25 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
